Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of bardoxolone methyl in autosomal dominant polycystic kidney disease
2018-004651-20Phase 3Unknown
- Sponsor
- Reata Pharmaceuticals
- Start
- Aug 2019
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bardoxolone methyl in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Reata Pharmaceuticals. Primary endpoint: Off-treatment change from baseline in eGFR at Week 52. Status: unknown.
02
Drugs
bardoxolone methyl
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2018-004651-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004651-20.